November is Lung Cancer Awareness Month!

  Help Raise Awareness about The Symptoms of Lung Cancer by sharing our BREATHE poster LFNZ-BREATHE-Symptoms-Poster Help raise awareness about Lung Cancer Risk Factors by sharing our Risk Factors poster Risk If you or someone you care about has been diagnosed with lung cancer, please view and share our patient introductory letter. We are here […]

Questions to ask your lung cancer specialist

If you or someone you care about has been diagnosed with lung cancer, Lung Foundation New Zealand (LFNZ) is here to support you. Here are some examples of questions patients (and carers) might want to ask their specialist; Q. Can we make arrangements to have my tumour tested using comprehensive genomic testing to inform my treatment? […]

Pharmac funds immunotherapy drug Durvalumab for Lung Cancer

Pharmac is now funding a new immunotherapy medicine called durvalumab (Imfinzi) which could be life-changing for the 300 patients diagnosed with Stage 3 non-small cell lung cancer every year in New Zealand. Durvalumab is the first immunotherapy drug to be funded for lung cancer in New Zealand and it has the potential to control cancer beyond […]

Cancer Non-Governmental Organisations (CANGO)

A meeting of Cancer Non-Governmental Organisations (CANGO) was hosted by CANGO, chairman; Peter Fergusson (CEO of Leukaemia & Blood Cancer NZ) on Monday 1st August 2022 (in person and online). Lung Foundation New Zealand is an active member of CANGO. Members collaborate on key issues facing the sector and through advocacy to improve the cancer […]

World Lung Cancer Day, 1st August 2022

Lung Foundation New Zealand observed World Lung Cancer Day to honour and unite all kiwis that have been affected by New Zealand’s Biggest Cancer Killer. The purpose of World Lung Cancer Day is to raise awareness about lung cancer and its global impact, to inform and educate an understanding of lung cancer risks and the […]

Pharmac issue RFP for immunotherapy

We are pleased to finally see a RFP for lung cancer immunotherapy issued. When immunotherapy treatment is funded for stage four lung cancer (NSCLC), it will be life changing for approximately 26 patients every week.. The combined voice of; patients, carers, patients family’s, health care professionals, specialists, researchers, advocates and community has made this possible. […]

Lung Foundation at the NZ Lung Cancer Conference

Lung Foundation New Zealand representatives; Chief Executive, Philip Hope and Assoc Prof of Oncology, Chris Atkinson attended and presented at the NZ Lung Cancer Conference. 2022 July – NZ Lung Cancer Conference Click to view the conference programme. https://az659834.vo.msecnd.net/eventsairseasiaprod/production-outshine-public/0fa313da4ba547a5a8d74d4cdb36241e  

Lung Foundation NZ’s response to Budget 2022

Lung Foundation New Zealand Tuapapa Pukahukahu Aotearoa understands there are many pressures on government (Pharmac too), especially in 2022. We acknowledge and support the philosophy the government has employed with its response to covid and reducing the impacts of covid, which is informed by scientific evidence and well-being; dedicated to reducing the burden on the […]

Analysis of Cancer Medicine Availability in Aotearoa by Te Aho o Te Kahu

While we acknowledge Te Aho o Te Kahu for publishing this report, it is merely telling us what we already know. Notable is the timing of this report which well follows the review of Pharmac (and prior to that the flawed health system review..). Till now Te Aho o Te Kahu hasn’t acknowledged the huge […]

Lung Foundation NZ acknowledges decision to fund durvalumab

Pharmac’s decision to fund immunotherapy treatment durvalumab (imfinzi) for stage 3 lung cancer is a small step forward. Lung Foundation New Zealand (LFNZ) acknowledges the leaders and clinical advisors at Pharmac and the key people at AstraZeneca for getting durvalumab (imfinzi) across the line. This funding decision also highlights extreme inequities with access to treatments […]